Efficacy of Kangliuwan for Recurrent Grade IV Glioma

• Conditions: Recurrence; Glioma of Brain

• Registration Number: NCT03949192
• Lead Sponsor: Xuanwu Hospital, Beijing

Brief Summary

A Prospective Exploratory Clinical Study to explore the efficacy of Hospital Traditional Chinese Medicine Preparation Kangliuwan for Recurrent Grade IV Glioma.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-05-11
• Study First Submitted QC: 2019-05-11
• Study First Posted: 2019-05-14
• Study Start: 2019-06-28
• Status Verified: 2020-04
• Last Update Submitted: 2020-04-30
• Last Update Posted: 2020-05-05
• Primary Completion: 2021-06
• Study Completion: 2021-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. The patient signed "informed consent" voluntarily;
2. The age of patient is between 18 and 80 years;
3. KPS score ≥40 ; The patient has normal liver and kidney function Normal heart function Better follow-up and compliance;

Exclusion Criteria

1. The patient did not sign "informed consent" or signed unvoluntarily.
2. Non-glioma patients
3. Active infection
4. Human immunodeficiency virus (HIV) positive
5. Hepatitis C or hepatitis B infective
6. Pregnancy or breast-feeding women
7. Patients did not agree to use effective contraception during treatment and the following 3 months.
8. Patients also participated in other clinical studies.
9. The subjects researchers believe are not suitable for participation or completion of the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in tumor volume	3 months	the volume of tumor decreased after taking Kangliuwan

Trial Locations

Locations (1)

Xuanwu Hospital; 🇨🇳 Beijing, Beijing, China